Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Uterine Cervical Neoplasms 2Urinary Bladder Neoplasms 2Prostatic Neoplasms 2Uterine Neoplasms 1Pancreatic Neoplasms 1Esophageal Neoplasms 1Endometrial Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

Paclitaxel 37Carboplatin 28pembrolizumab 19Surveys and Questionnaires 11temsirolimus 10Radiotherapy 10Cisplatin 10Doxorubicin 9Bevacizumab 9lenvatinib 8Docetaxel 8Nivolumab 7Metformin 7Gemcitabine 7Early Intervention, Educational 7Counseling 7Sirolimus 6Radiation 6Megestrol Acetate 6Indocyanine Green 6olaparib 5Topotecan 5Therapeutics 5Psychiatric Rehabilitation 5Methods 5Letrozole 5Ipilimumab 5Chemotherapy, Adjuvant 5ridaforolimus 4Trastuzumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Neoplasms × ferumoxtran-10 × Clear all
NCT00416455 2019-07-23

Fludeoxyglucose (FDG) F 18 PET Scan, CT Scan, and Ferumoxtran-10 MRI Scan Before Chemotherapy and Radiation Therapy in Finding Lymph Node Metastasis in Patients With Locally Advanced Cervical Cancer or High-Risk Endometrial Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
384 enrolled 23 charts
Gynecologic

Uterine Cervical Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡